May 6, 2024

Willkie advised PAI Partners on its acquisition of a majority stake in Vamed’s European rehabilitation business from global healthcare group Fresenius SE & Co. KGaA.
On May 2, PAI announced its strategic partnership with Fresenius whereby it will make a majority investment in Vamed’s rehabilitation business. Upon completion of the transaction, PAI will hold a 67% stake in the business and Fresenius will retain a 33% stake. The rehabilitation business comprises 67 facilities with 9,100 beds and approximately 9,500 employees across Germany, Austria, Switzerland, the Czech Republic and the UK.
PAI Partners is a pre-eminent private equity firm investing in market-leading companies across the globe. The firm has approximately €27 billion of assets under management.

The Willkie team was led by partner Dr. Axel Wahl and included partners Dr. Michael Ilter, Dr. Patrick Meiisel, Dr. Bettina Bokeloh, Anne Kleffmann, Dr. Richard Roeder, Jan Wilms, Faustine Viala and David Kupka; counsel Dr. Florian Dendl, Christian Sperling, Henning Aufderhaar, Wulf Kring, Martin Waśkowski and Maximilian Mayer; and associates Dr. Tobias Gerigk, Dr. Patrick Kemper, Nils Hoernig, Dr. Maximilian Schatz, Dr. Laurin Havlik, Dr. Philipp Steinhausen, Philip Thürmer, Leota Walter, Sophie Wollenweber, Sascha Winkler and Marcel Seemaier. 
David Kupka
David Kupka National Partner Antitrust & Competition
Martin Waskowski
Martin Waskowski Counsel Executive Compensation & Employee Benefits
Nils Hoernig Associate Corporate & Financial Services